Grade 1 endometrioid cancer in an obese woman with diabetes asking for keyhole surgery
Zainab is 61, gravida 5 para 4, with a BMI of 38, type 2 diabetes (HbA1c 8.4%) and treated hypertension, referred with four months of postmenopausal bleeding. Endometrial biopsy shows grade 1 endometrioid adenocarcinoma. Transvaginal ultrasound: endometrial thickness 18 mm. Pelvic MRI: tumour confined to the corpus, myometrial invasion less than 50%, no cervical stromal, adnexal or nodal involvement; CA-125 is 27 U/mL. She smokes 20 cigarettes daily and has mild renal impairment with an eGFR of 62 mL/min/1.73 m². She has read about 'keyhole surgery' and wants it. Her daughter, a nurse, asks whether 'gene testing on the tumour can let her avoid chemotherapy'.
1. Set out your surgical plan and justify your choice of nodal assessment and route of surgery.
Read the worked answer
Clinical stage IA grade 1, but staging is surgical and final staging comes from the specimen.
Procedure: total hysterectomy with bilateral salpingo-oophorectomy, peritoneal washings (optional) and sentinel lymph node biopsy using cervical injection of indocyanine green (with blue dye as backup), with pathological ultrastaging. Sentinel node biopsy is the standard of care for presumed early-stage, low-grade endometrial cancer: it yields higher detection of micrometastases with far less lymphoedema than systematic pelvic lymphadenectomy, and a negative sentinel node allows lymphadenectomy to be omitted. If no node is identified on a side, perform a side-specific lymphadenectomy. Do not morcellate the uterus.
Route: laparoscopic or robotic staging is oncologically equivalent and is preferable for obesity where expertise exists - but BMI 38, diabetes, a large uterus, limited Trendelenburg tolerance and previous surgery raise the conversion and complication rate. Open laparotomy is a defensible, not a failed, choice, and she should be consented for conversion. Do not let her preference override the surgical assessment.
Supportive care: glycaemic control pre- and post-operatively, LMWH plus mechanical prophylaxis and extended LMWH for 28 days after major pelvic cancer surgery, early mobilisation, careful haemostasis, and antibiotic prophylaxis. Offer smoking cessation before admission; it reduces respiratory and wound complications more than any other single measure.
2. The final pathology confirms stage IA grade 1 with no lymphovascular space invasion and negative sentinel nodes. How do you decide on adjuvant treatment, and how do you answer the daughter's question about tumour gene testing?
Read the worked answer
For stage IA grade 1 without lymphovascular space invasion, no adjuvant treatment is indicated. PORTEC-1 and GOG-99 showed no survival advantage from pelvic radiotherapy in low-risk disease, and vaginal brachytherapy would add vaginal morbidity and cost for no benefit; surgery alone gives over 95% disease-specific survival. Adjuvant treatment becomes relevant with substantial lymphovascular space invasion, grade 3, deeper invasion (high–intermediate risk: vaginal brachytherapy, as in PORTEC-2) or nodal involvement (external beam radiotherapy with chemotherapy, as in PORTEC-3).
Molecular classification changes this - ask for it on the specimen:
- POLE ultramutated: excellent prognosis; adjuvant treatment can be safely de-escalated even with higher grade.
- MMR-deficient/MSI-high: intermediate prognosis; also a screen for Lynch syndrome (MLH1 promoter methylation, then germline testing for MLH1, MSH2, MSH6, MSH1/PMS2 loss).
- NSMP (no specific molecular profile): intermediate.
- p53 abnormal: high risk - adjuvant chemotherapy should be considered even in apparent early-stage disease, based on PORTEC-3.
So the daughter's question is well aimed but slightly misdirected: the useful 'gene test' is immunohistochemistry for p53 and mismatch repair proteins on the tumour, and it guides whether chemotherapy or radiotherapy is needed rather than avoiding it. If Lynch syndrome is suspected, refer to clinical genetics and arrange colonoscopy - this has implications for her children.
3. List the key preoperative optimisation steps and the specific consent points you would cover before this operation.
Read the worked answer
Optimisation:
- Improve glycaemic control with the anaesthetist and physician; an HbA1c of 8.4% predicts wound infection and should be addressed even if surgery cannot wait indefinitely.
- Smoking cessation, chest physiotherapy and incentive spirometry; quantify with spirometry if COPD is suspected.
- Document renal function (eGFR 62) and review metformin and antihypertensives around the perioperative period; avoid nephrotoxic agents.
- Assess and document VTE risk, fit mechanical prophylaxis, prescribe extended LMWH, and consider a pre-operative anaesthetic review for a BMI of 38 (airway, obstructive sleep apnoea screening, positioning and thromboprophylaxis).
- Correct anaemia if present; ensure adequate staffing and equipment for a potentially long operation in a morbidly obese woman.
Consent:
- Conversion to laparotomy; risk of major haemorrhage and transfusion.
- Ureteric, bladder and bowel injury (about 1–2% in benign-looking pelvic surgery); lymphocele and lower-limb lymphoedema (much lower with sentinel node biopsy than full lymphadenectomy); sexual dysfunction and vaginal cuff problems.
- The possibility of adjuvant radiotherapy after the histology is known, and of further surgery if nodes are positive.
- That bilateral oophorectomy is part of staging and removes endogenous oestrogen; HRT is not required at 61 but sexual and bone health should be discussed.
- That the final stage may differ from the MRI, and that she will be discussed at a multidisciplinary meeting.